Quick Answer
Xilio Therapeutics, Inc. reported Stockholders Equity of $35.27 million for the year ending 2025.
- Xilio Therapeutics, Inc. showed an increase of +100.4% in Stockholders Equity from 2024 to 2025.
- This data is from Xilio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$37.55 million | Q2 2020: -$48.90 million | Q3 2020: -$63.03 million | Q1 2021: -$99.14 million | Q2 2021: -$121.31 million | Q3 2021: -$136.46 million | Q1 2022: $166.12 million | Q2 2022: $144.22 million | Q3 2022: $126.30 million | Q1 2023: $84.79 million | Q2 2023: $67.38 million | Q3 2023: $52.50 million | Q1 2024: $25.77 million | Q2 2024: $33.42 million | Q3 2024: $20.97 million | Q1 2025: $10.70 million | Q2 2025: $7.07 million | Q3 2025: -$8.10 million.
- Over the full 7 years of available data (2019 to 2025), Xilio Therapeutics, Inc.'s Stockholders Equity has grown by 219.5%.
- Historical annual values: Fiscal year 2025: $35.27 million | Fiscal year 2024: $17.60 million | Fiscal year 2023: $36.83 million | Fiscal year 2022: $105.65 million | Fiscal year 2021: $185.43 million | Fiscal year 2020: -$83.29 million | Fiscal year 2019: -$29.52 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: